What are the latest funding news in the neurotechnology market? (September 2026)
Download our beautiful pitch about the neurotechnology market
In our neurotechnology market deck, you will find everything you need to understand the market
This review covers 12 disclosed neurotechnology funding announcements made between late May and early August 2026.
The selected companies build brain-computer interfaces, neuromodulation systems, EEG tools, neuroimaging products, and clinical neuroanalytics platforms.
And if you want to better understand this new industry, you can download our pitch covering the neurotechnology market.
Insights
- Early-stage neurotechnology financing dominated this group: nine of the 12 disclosed deals were angel, pre-seed, seed, pre-Series A, or otherwise early-stage rounds.
- China accounted for at least $123M of recently disclosed funding across four BCI and ultrasound neuromodulation companies, showing strong capital concentration around neural-interface hardware.
- Brain-computer interfaces and neuromodulation represented seven of the 12 companies, while EEG monitoring, neurodiagnostics, imaging, and connectomics formed the other major neurotechnology funding themes.
- Three later-stage rounds from Epitel, WISE, and Omniscient Neurotechnology totalled $88M, indicating that clinical and commercial neurotechnology platforms can still attract sizable growth capital.
- Ultrasound-based neurotechnology appeared in three Chinese financings, reflecting investor interest in non-invasive approaches to brain stimulation and neural signal interaction.
- Stroke care was a recurring clinical focus, with Aurenar developing vagus-nerve stimulation for rehabilitation and Wellumio building portable neuroimaging for rapid stroke assessment.
- Several disclosed amounts need careful interpretation: Hemispheric reported cumulative funding rather than a clearly separated new round, while Fluent BCI was reported at different pre-seed totals.
As this chart shows, and as featured in our neurotechnology market deck, search interest in neurotechnology has been climbing steadily
Summary table of the latest funding deals in the neurotechnology market as of September 2026
We define the neurotechnology market as products that directly measure, stimulate, or computationally interface with the human nervous system for clinical or validated functional outcomes.
We include neurodevices and their enabling software such as BCIs, neuromodulation systems, and neurodiagnostic/monitoring tools such as EEG and related analytics.
We exclude pharmaceuticals, general-purpose imaging infrastructure not purpose-built for neuro, and standalone wellness or mental-health apps that do not directly capture or act on nervous-system signals.
You can also read our detailed analysis to understand how funding activity in the neurotechnology market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the neurotechnology market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Active Technology | 4 August 2026 | About $46M | Angel | Implantable BCI & Neural Interface |
| Aurenar | 28 July 2026 | $5.7M | Seed | Non-Invasive Neuromodulation & Stroke Rehabilitation |
| Epitel | 28 July 2026 | $26M | Series B | EEG & Neurodiagnostic Monitoring |
| Wellumio | 24 July 2026 | $9.75M | Pre-Series A | Neurodiagnostic Imaging & Stroke Assessment |
| Hemispheric | 15 July 2026 | $52M cumulative | Early-Stage Funding | EEG Analytics & Neurodiagnostics |
| Gestala | 3 July 2026 | About $62M | Angel+ | Ultrasound BCI & Neuromodulation |
| Sisen Technology | 1 July 2026 | At least $1.4M | Seed | Ultrasound BCI & Neuromodulation |
| Fluent BCI | 30 June 2026 | About $1.3M | Pre-Seed | Speech BCI & Neural Signal Decoding |
| Neuronostics | 30 June 2026 | $4.1M | Seed | EEG Neurodiagnostics & Epilepsy |
| WISE | 17 June 2026 | $34.8M | Series D | Implantable Neuromodulation |
| BCI-Sonics | 8 June 2026 | At least $14M | Angel / Angel+ | Ultrasound BCI & Neuromodulation |
| Omniscient Neurotechnology | 29 May 2026 | $27.2M | Series D | Connectomic Brain Mapping & Clinical Neuroanalytics |
All the latest funding deals in the neurotechnology market as of September 2026
Active Technology raised about $46M in an angel round during August 2026.
When was it?
Active Technology announced the financing on 4 August 2026.
Who are they?
Active Technology develops invasive brain-computer interfaces that combine flexible electrodes, neural-decoding chips, and algorithms for motor, visual, and other neural applications.
Geographical focus?
Active Technology is focused on China, with development work aimed at clinical translation in the local healthcare ecosystem.
Why do we include them in the neurotechnology market?
Active Technology belongs in the neurotechnology market because its implantable BCI systems directly record and decode signals from the human nervous system.
What is the company stage?
Active Technology was at angel and preclinical development stage at the time of the financing.
How much did they raise?
Active Technology raised about $46M, or RMB 330M, in the disclosed round.
What round is it?
Active Technology completed an angel financing round led by Zhongke Chuangxing.
Why did they raise?
Active Technology raised the capital to expand sites and equipment, advance clinical trials, and grow its team.
Aurenar raised $5.7M in a seed round during July 2026.
When was it?
Aurenar announced its seed financing on 28 July 2026.
Who are they?
Aurenar develops an ear-worn vagus-nerve stimulation device designed to support stroke recovery.
Geographical focus?
Aurenar is a United States-focused company working toward broader use in stroke-care settings.
Why do we include them in the neurotechnology market?
Aurenar belongs in the neurotechnology market because its device directly stimulates the vagus nerve for a clinical rehabilitation outcome.
What is the company stage?
Aurenar was at seed and clinical-development stage when the round was announced.
How much did they raise?
Aurenar raised $5.7M in the disclosed financing.
What round is it?
Aurenar completed a seed round co-led by Go Red for Women Venture Fund and Solas BioVentures.
Why did they raise?
Aurenar raised the funding to advance clinical development and prepare for broader stroke-care use.
This chart, featured in our neurotechnology market deck, compares the main business model options for neurotechnology device platforms
Epitel raised $26M in a Series B round during July 2026.
When was it?
Epitel announced its Series B financing on 28 July 2026.
Who are they?
Epitel develops wireless wearable EEG systems that monitor seizures and detect neurological events.
Geographical focus?
Epitel is based in the United States and serves healthcare providers seeking scalable neurological monitoring tools.
Why do we include them in the neurotechnology market?
Epitel belongs in the neurotechnology market because its wearable EEG products directly measure brain activity for clinical monitoring.
What is the company stage?
Epitel was at commercial growth stage and already had an FDA-cleared product.
How much did they raise?
Epitel raised $26M in the disclosed round.
What round is it?
Epitel completed a Series B round co-led by Catalyst Health Ventures and Genoa Ventures.
Why did they raise?
Epitel raised the capital to scale commercial adoption, product development, and health-system deployments.
Wellumio raised $9.75M in a pre-Series A round during July 2026.
When was it?
Wellumio announced its pre-Series A financing on 24 July 2026.
Who are they?
Wellumio develops portable neuroimaging systems purpose-built to support rapid stroke assessment.
Geographical focus?
Wellumio is headquartered in New Zealand and is targeting international healthcare markets.
Why do we include them in the neurotechnology market?
Wellumio belongs in the neurotechnology market because its neuroimaging product is designed specifically to assess brain conditions in acute stroke care.
What is the company stage?
Wellumio was at pre-Series A stage, with clinical validation and commercialization work underway.
How much did they raise?
Wellumio raised $9.75M in the disclosed financing.
What round is it?
Wellumio completed a pre-Series A round.
Why did they raise?
Wellumio raised the funding to advance clinical validation, product development, and market entry.
This chart, featured in our neurotechnology market deck, shows why Neuropace is winning in neurotechnology
Hemispheric disclosed $52M in cumulative funding during July 2026.
When was it?
Hemispheric announced the funding update on 15 July 2026.
Who are they?
Hemispheric develops EEG-based NeuroAI analytics for neurological diagnosis and brain-signal interpretation.
Geographical focus?
Hemispheric operates across North American healthcare and research markets.
Why do we include them in the neurotechnology market?
Hemispheric belongs in the neurotechnology market because its software analyzes EEG signals to support neurological diagnosis and clinical interpretation.
What is the company stage?
Hemispheric was at an early technology-development stage when the funding update was reported.
How much did they raise?
Hemispheric disclosed $52M in cumulative funding, while the exact amount of the newly announced financing was not separated publicly.
What round is it?
Hemispheric described the event as early-stage funding rather than a clearly named venture round.
Why did they raise?
Hemispheric used the financing to expand neurodiagnostic AI research, validation, and product development.
Gestala raised about $62M in an Angel+ round during July 2026.
When was it?
Gestala announced its latest Angel+ financing on 3 July 2026.
Who are they?
Gestala develops ultrasound-based brain-computer interfaces and deep neuromodulation systems.
Geographical focus?
Gestala is focused on China, with plans to move its technology through research, clinical translation, and industrialization.
Why do we include them in the neurotechnology market?
Gestala belongs in the neurotechnology market because its systems use focused ultrasound to interface with and stimulate the brain.
What is the company stage?
Gestala was at Angel+ and preclinical development stage at the time of the round.
How much did they raise?
Gestala raised about $62M in the latest disclosed Angel+ tranche.
What round is it?
Gestala completed an Angel+ round with new participation from HSG, Lens Technology, Sinovation Ventures, and C Capital.
Why did they raise?
Gestala raised the capital to accelerate ultrasound BCI research, clinical translation, and industrialization.
In our neurotechnology market deck, we identify pain points entrepreneurs should prioritize
Sisen Technology raised at least $1.4M in a seed round during July 2026.
When was it?
Sisen Technology announced its seed financing on 1 July 2026.
Who are they?
Sisen Technology develops ultrasound-based brain interfaces and technology for blood-brain-barrier modulation.
Geographical focus?
Sisen Technology is focused on the Chinese neurotechnology market and early clinical translation work.
Why do we include them in the neurotechnology market?
Sisen Technology belongs in the neurotechnology market because its ultrasound platform is designed to interact directly with brain tissue and neural pathways.
What is the company stage?
Sisen Technology was at seed and early research-and-development stage when the financing was announced.
How much did they raise?
Sisen Technology raised at least $1.4M in the disclosed financing.
What round is it?
Sisen Technology completed a seed round, although the full investor syndicate was not publicly re-verified.
Why did they raise?
Sisen Technology raised the funding to advance prototypes, experiments, and clinical translation.
Fluent BCI raised about $1.3M in a pre-seed round during June 2026.
When was it?
Fluent BCI announced its pre-seed financing on 30 June 2026.
Who are they?
Fluent BCI develops a sub-scalp neural interface that decodes intended speech into text using EEG-like signals and AI.
Geographical focus?
Fluent BCI is based in Australia and is developing technology for people with communication impairments.
Why do we include them in the neurotechnology market?
Fluent BCI belongs in the neurotechnology market because its speech BCI captures and computationally decodes neural signals.
What is the company stage?
Fluent BCI was at pre-seed and preclinical stage, and its product was not yet cleared for sale.
How much did they raise?
Fluent BCI initially reported about $1.3M, while later reporting described a $2M pre-seed total.
What round is it?
Fluent BCI completed a pre-seed round that included a disclosed US$350K investment from Galileo Ventures.
Why did they raise?
Fluent BCI raised the capital to develop InScribe, improve speech decoding, and progress toward clinical validation.
This market map, featured in our neurotechnology market deck, highlights top companies and startups in the neurotechnology market
Neuronostics raised $4.1M in new seed funding during June 2026.
When was it?
Neuronostics announced its financing on 30 June 2026.
Who are they?
Neuronostics uses EEG-derived biomarkers and analytics to help clinicians diagnose and monitor epilepsy.
Geographical focus?
Neuronostics is based in the United Kingdom and is expanding into wider healthcare markets.
Why do we include them in the neurotechnology market?
Neuronostics belongs in the neurotechnology market because its platform analyzes EEG activity to support neurological diagnosis and patient monitoring.
What is the company stage?
Neuronostics was at seed stage, with commercial and clinical expansion underway.
How much did they raise?
Neuronostics raised $4.1M in new investment.
What round is it?
Neuronostics completed a seed or new-investment financing round.
Why did they raise?
Neuronostics raised the funding to expand clinical evidence, regulatory work, and commercialization.
WISE raised $34.8M in a Series D round during June 2026.
When was it?
WISE announced its Series D financing on 17 June 2026.
Who are they?
WISE develops implantable electrodes and neurostimulation systems, including spinal stimulation technology.
Geographical focus?
WISE operates across European and United States healthcare markets.
Why do we include them in the neurotechnology market?
WISE belongs in the neurotechnology market because its implantable systems directly stimulate neural pathways for clinical treatment applications.
What is the company stage?
WISE was at Series D stage, with clinical and commercial programs already underway.
How much did they raise?
WISE raised $34.8M in the disclosed financing.
What round is it?
WISE completed a Series D round, although the complete investor syndicate was not publicly re-verified.
Why did they raise?
WISE raised the capital to advance clinical programs, regulatory milestones, and commercialization.
This chart, featured in our neurotechnology market deck, shows annual funding in neurotechnology startups
BCI-Sonics raised at least $14M in angel funding during June 2026.
When was it?
BCI-Sonics announced its financing on 8 June 2026.
Who are they?
BCI-Sonics develops AI-guided focused-ultrasound brain-computer interfaces and neuromodulation systems.
Geographical focus?
BCI-Sonics is focused on China, where it is advancing hardware, algorithms, and early commercialization plans.
Why do we include them in the neurotechnology market?
BCI-Sonics belongs in the neurotechnology market because its focused-ultrasound systems are designed to interact with the brain for BCI and neuromodulation applications.
What is the company stage?
BCI-Sonics was at angel and Angel+ stage, with early technical development underway.
How much did they raise?
BCI-Sonics raised at least $14M across the disclosed angel financing activity.
What round is it?
BCI-Sonics completed an angel or Angel+ financing round.
Why did they raise?
BCI-Sonics raised the funding to accelerate hardware development, algorithms, preclinical work, and commercialization planning.
Omniscient Neurotechnology raised $27.2M in a Series D round during May 2026.
When was it?
Omniscient Neurotechnology announced its Series D financing on 29 May 2026.
Who are they?
Omniscient Neurotechnology maps brain connectivity with connectomics software that supports neurological and neurosurgical decision-making.
Geographical focus?
Omniscient Neurotechnology is active in the United States and serves hospitals across global healthcare markets.
Why do we include them in the neurotechnology market?
Omniscient Neurotechnology belongs in the neurotechnology market because its clinical software analyzes brain connectivity to guide neurological care.
What is the company stage?
Omniscient Neurotechnology was at Series D and commercial-growth stage when the round was announced.
How much did they raise?
Omniscient Neurotechnology raised $27.2M in the disclosed financing.
What round is it?
Omniscient Neurotechnology completed a Series D round.
Why did they raise?
Omniscient Neurotechnology raised the capital to expand clinical deployments, product capabilities, and global commercial reach.
Related blog posts
- The evolution of funding activity in the neurotechnology market
- How strong is fundraising in the neurotechnology market right now?
- The main fundraising trends in the neurotechnology market
- What are the top startups in the neurotechnology market?
